Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year High Following Analyst Upgrade

Vera Therapeutics, Inc. (NASDAQ:VERA)’s share price reached a new 52-week high during trading on Friday after Bank of America raised their price target on the stock from $48.00 to $66.00. Bank of America currently has a buy rating on the stock. Vera Therapeutics traded as high as $51.72 and last traded at $51.2720, with a volume of 751409 shares. The stock had previously closed at $47.69.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Pivotal Research set a $73.00 price objective on Vera Therapeutics in a research note on Friday, December 5th. The Goldman Sachs Group increased their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday. Wedbush lifted their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Finally, Evercore ISI lifted their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $74.83.

Insiders Place Their Bets

In other news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president owned 47,839 shares in the company, valued at $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $42.50 per share, with a total value of $249,985.00. Following the transaction, the director directly owned 5,882 shares of the company’s stock, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Quarry LP boosted its position in shares of Vera Therapeutics by 25.0% in the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after purchasing an additional 500 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Vera Therapeutics by 13.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after purchasing an additional 615 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Vera Therapeutics by 2.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock worth $744,000 after purchasing an additional 816 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Up 7.2%

The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.78 and a beta of 1.21. The business’s 50 day moving average is $33.47 and its 200 day moving average is $27.17.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period in the prior year, the firm posted ($0.85) earnings per share. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.